Amit Seth, MD
Endocrinology, Diabetes & Metabolism · Belleville, NJNPI 1316196165
Payments from drug & device makers
Across 413 payments — averaging $107.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$36K
- Medtronic$3K
- Abbott$748
- Lilly USA, LLC$620
- Amgen$445
- Boehringer Ingelheim$418
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$34,30077%
- Travel & lodging$2,3415%
- Food & beverage$7,70617%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 68 | $35,645 |
| Medtronic(2 entities) | 41 | $3,064 |
| Abbott | 30 | $748 |
| Lilly USA, LLC | 40 | $620 |
| Amgen(2 entities) | 30 | $445 |
| Boehringer Ingelheim | 26 | $418 |
| Amneal Pharmaceuticals LLC | 24 | $367 |
| Sanofi-aventis U.S. LLC | 24 | $359 |
| Dexcom, Inc. | 20 | $358 |
| Tandem Diabetes Care, Inc. | 8 | $313 |
| AbbVie | 17 | $275 |
| Xeris Pharmaceuticals, Inc. | 15 | $252 |
| Novo Nordisk | 14 | $245 |
| Pfizer | 9 | $242 |
| Insulet Corporation | 9 | $191 |
| Cequr Corporation | 5 | $154 |
| Corcept Therapeutics | 6 | $113 |
| La Jolla Pharmaceutical Company | 1 | $97 |
| Exact Sciences | 2 | $44 |
| GSK | 2 | $33 |
| Mannkind Corporation | 2 | $33 |
| UCB, Inc. | 2 | $31 |
| Merck | 2 | $30 |
| Recordati_rare_diseases_inc. | 2 | $30 |
| IBSA Pharma Inc. | 2 | $26 |
| Bayer | 1 | $25 |
| Averitas Pharma Inc. | 1 | $24 |
| Bigfoot Biomedical Inc | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $19 |
| Madrigal Pharmaceuticals | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $18 |
| Echosens North America, Inc. | 1 | $17 |
| Incyte Corporation | 1 | $16 |
| BD | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
| Embecta Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$35,155
- Minimed 670G System$1,036
- MINIMED 780G$853
- FREESTYLE LIBRE 3$145
- DEXCOM G6 TRANSMITTER$122
- MINIMED 770G$106
- PAXLOVID$102
How this compares
$44,357 in reported general payments places this provider in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 339 | $434,353 |
| MounjaroTirzepatide | 236 | $429,732 |
| FarxigaDapagliflozin Propanediol | 201 | $232,739 |
| OzempicSemaglutide | 138 | $228,641 |
| TrulicityDulaglutide | 132 | $217,036 |
| JanuviaSitagliptin Phosphate | 128 | $130,276 |
| Bydureon BciseExenatide Microspheres | 75 | $87,956 |
| RybelsusSemaglutide | 38 | $72,266 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 65 | $69,471 |
| TradjentaLinagliptin | 58 | $68,844 |
| Tresiba Flextouch U-100Insulin Degludec | 77 | $67,089 |
| JanumetSitagliptin Phos/Metformin Hcl | 68 | $65,000 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 31 | $62,487 |
| ProliaDenosumab | 35 | $61,211 |
| Humalog Kwikpen U-100Insulin Lispro | 141 | $50,819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $620 | $658,927414 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Synjardy Xr | $418 | $544,781425 claims |
| Novo NordiskOzempic, Rybelsus | $245 | $300,907176 claims |
| MerckJanuvia, Janumet Xr, Janumet | $30 | $264,747261 claims |
| AstraZenecaFarxiga | $35,645 | $232,739201 claims |
| AmgenProlia | $445 | $61,21135 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $359 | $24,69616 claims |
| PfizerEliquis | $242 | $22,14027 claims |
| GSKTrelegy Ellipta | $33 | $17,22024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Belleville
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Taher ModarressiPennington$414K
- Navtika DesaiHillsborough$408K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Sunil AsnaniBrick$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.